Sofosbuvir
9 articles
Gilead’s HCV Drug Sofosbuvir Approved by the FDA but Accessible for How Many?
Press Release – 9 December 2013 / Bangkok – Paris – Basel – London – New York
On 6 Dec 2013, FDA approved Gilead’s HCV drug Sovaldi. Yet its anticipated price tag of $80,000 will ensure this drug remains out of reach for the vast majority of people with HCV. More
International Liver Conference: Activists Demand Affordable Hepatitis C Treatment
Pills cost pennies, greed costs lives.
As the 49th International Liver Conference is officially starting, activist held a demonstration in the main hall to raise the issue of access to hepatitis C treatment in LMICs. More
AIDS 2014: Activists Hold Die-In to Protest High Price of Gilead’s Hepatitis C Drug
"HCV drugs are priced out of reach and out of control", Michel Sidibé, UNAIDS
Treatment activists at the 20th International AIDS Conference held a die-in to protest the exorbitant pricing of Sovaldi (sofosbuvir), Gilead’s new hepatitis C drug. More
Gilead’s License on Hepatitis C Drugs, Sofosbuvir and Ledipasvir: a Fool’s Bargain
Myths and facts
Gilead’s license is a fool’s bargain that inhibits access for nearly half the world’s HCV population. More
Gilead: Stop Blocking Access to Hepatitis C Treatment
Thousands of activists urge company to change its policies on eve of shareholder meeting
On the eve of Gilead’s annual shareholder meeting, thousands of activists have demanded that Gilead change its policies that deny access to treatment for millions in developing countries. More
